Debut Plus

1,125.5

-26.85 -2.33%

As of 09 Sept 2026 · delayed

NSE Listed

LT-ASM · ASM 2
What does LT-ASM · ASM 2 mean?
NSE · Long Term Additional Surveillance Measure (ASM 2)LT-ASM is the joint SEBI/exchange framework for SUSTAINED abnormal price moves (contrast ST-ASM's 5–15-day spikes). Entry is beta-adjusted price variation versus the Nifty (e.g. 3-month high-low above 150% plus the stock's β × index move) along with client-concentration checks. Stages I–IV escalate from a 5% price band through 100% margin to Trade-for-Trade with an additional surveillance deposit. Practical meaning: the exchange still considers the price action abnormal — tighter bands and elevated margins continue even if another measure (like ESM) has lifted. A stock can sit under LT-ASM on both exchanges via either exchange's shortlisting; it is a preventive cost-of-speculation measure, not an adverse finding against the company.Criteria: High 3-month / 12-month high-low price variation, close-to-close price variation, client concentration, number of price-band hits, market-wide position limit and P/E — applied in graded Stages I–IV with escalating margin and price-band curbs.Exchange notice · 2026-08-13

Sakar Healthcare Limited (SAKAR)

Volume: 1,41,701Avg Vol 1W: 2,63,502Avg Vol 1M: 2,02,793.9552W Range:3261,211
Key Ratios
Checked 8h ago
Market Cap₹2,564 Cr
Current Price₹1,125.5
Previous Close₹1,152.35
High / Low (52w)₹1,211 / ₹326
Volume1,41,701
Avg Vol (1W)2,63,502
Avg Vol (1M)2,02,793.95
Stock P/E71.05
Book Value₹145.82
Dividend Yield0%
ROE9.4%
ROA7.5%
Revenue (TTM)₹254 Cr
Revenue Growth15.8%
Profit Margin13.27%
Total Debt₹54 Cr
Shares Outstanding2 Cr
Face Value₹10
EPS (TTM)₹16.22
P/B7.9
Debt / Equity0.26
50 DMA₹901.12
200 DMA₹649.18
Day change-2.33%
SurveillanceLT-ASM · ASM 2
Price Chart
1,125.5 230.06% · 1Y
115833413.5L
2025-09-10
2026-09-09

20-day avg volume: 2.0L shares

Pros
  • Company is almost debt-free.
Cons
  • Revenue fell 11% YoY.
  • Stock trades at a high P/E of 71.
Quarterly Results
MetricSept 2024Dec 2024Mar 2025Jun 2025Sept 2025Dec 2025Mar 2026Jun 2026
Revenue₹43 Cr₹43 Cr₹50 Cr₹53 Cr₹58 Cr₹70 Cr₹71 Cr₹73 Cr
EBITDA₹7 Cr₹7 Cr₹10 Cr₹8 Cr₹7 Cr₹13 Cr₹20 Cr₹16 Cr
Net Profit₹5 Cr₹5 Cr₹6 Cr₹5 Cr₹5 Cr₹10 Cr₹11 Cr₹10 Cr
EPS
Profit & Loss (Annual)
MetricMar 2025Mar 2025Jun 2025Sept 2025Dec 2025Mar 2026Mar 2026Jun 2026
Revenue₹50 Cr₹179 Cr₹53 Cr₹58 Cr₹70 Cr₹254 Cr₹71 Cr₹73 Cr
EBITDA₹10 Cr₹30 Cr₹8 Cr₹7 Cr₹13 Cr₹48 Cr₹20 Cr₹16 Cr
Net Profit₹6 Cr₹18 Cr₹5 Cr₹5 Cr₹10 Cr₹30 Cr₹11 Cr₹10 Cr
EPS7.9513.7
Balance Sheet
MetricMar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Total Assets₹115 Cr₹178 Cr₹268 Cr₹336 Cr₹389 Cr₹415 Cr₹481 Cr
Total Liabilities₹34 Cr₹79 Cr₹140 Cr₹163 Cr₹126 Cr₹130 Cr₹157 Cr
Equity₹81 Cr₹98 Cr₹127 Cr₹173 Cr₹262 Cr₹285 Cr₹324 Cr
Total Debt
Cash Flow
MetricMar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating₹22 Cr₹15 Cr₹36 Cr₹38 Cr₹142 Cr₹36 Cr₹53 Cr
Investing₹-22 Cr₹-47 Cr₹-90 Cr₹-74 Cr₹-52 Cr₹-31 Cr₹-28 Cr
Financing₹3 Cr₹32 Cr₹55 Cr₹41 Cr₹27 Cr₹-3 Cr₹-21 Cr
Free Cash Flow₹13 Cr₹4 Cr₹36 Cr₹38 Cr₹142 Cr₹36 Cr₹53 Cr
Shareholding
Promoter 52.52% Institutions 23.51% Public 23.98%
Efficiency & Working Capital
ROCE12.5%
Interest Coverage6.1
Dividend Payout
Debtor Days73 d
Inventory Days102 d
Payable Days75 d
Cash Conversion Cycle99 d
Working Capital Days174 d
Shareholding Details

As of 2026-06-30

Promoter52.5%
FII12.1%
DII11.4%
Institutions23.5%
Public24%
Promoter Pledge0%
No. of Shareholders14,734
Shareholding Pattern

Quarterly — figures in %. Latest 12 quarters.

PeriodSept 2023Dec 2023Mar 2024Jun 2024Sept 2024Dec 2024Mar 2025Jun 2025Sept 2025Dec 2025Mar 2026Jun 2026
Promoters54.2%53.2%53.2%53.2%53.2%53.6%53.6%52.9%52.9%52.9%52.9%52.5%
FIIs14%13.8%13.5%13.5%13.4%13.6%13.6%13.4%13.3%13%12.9%12.1%
DIIs0%10.6%0%0%0%0%0%0%0%11.4%11.3%11.4%
Public31.8%22.5%33.3%33.3%33.4%32.8%32.8%33.7%33.8%22.7%22.9%24%
Promoter Pledge0%0%0%0%0%0%0%0%0%0%0%0%
No. of Shareholders7,2997,0017,3867,3137,8678,5988,6088,1157,5657,0699,58014,734
Returns History (ROE / ROCE / ROA)
PeriodROEROCEROAP/E
202603
Major Shareholders (>1%)
NameCategoryStakeShares
Sanjay S ShahShareholding of Promoter and Promoter Group45%1.00 Cr
Tata Capital Healthcare Fund IiPublic Shareholding10.4%23,09,910
Hbm Healthcare Investments (cayman) LtdPublic Shareholding6.7%15,00,000
Shah AarshShareholding of Promoter and Promoter Group6.3%14,07,500
Cobra India (mauritius) LimitedPublic Shareholding3.9%8,75,780
Ritaben ShahShareholding of Promoter and Promoter Group1.1%2,45,000
Shah AyushiShareholding of Promoter and Promoter Group0.1%24,000
Board of Directors
NameDesignationYear
Sanjay S Shah.Chairman & Managing Director2025
Aarsh S ShahJoint Managing Director2025
Visalakshi ChandramouliNon-Exec & Non-Independent Dir2025
JIGNESH MUKUNDBHAI PARIKHIndependent Non Exe. Director2025
Khyati B. ShahIndependent Non Exe. Director2025
Sunil MaratheWhole Time Director- Technical2025
Megha Kamal SamdaniIndependent Non Exe. Director2025
Reeya KothariIndependent Non Exe. Director2025
Hiral Vinodbhai PatelIndependent Non Exe. Director2025
Bharat SoniCompany Sec. & Compli. Officer2025
Segments — Product
SegmentRevenueShare
Manufacturing of Pharmaceutical pro₹0 Cr
Segments — Geography
RegionRevenueShare
Domestic₹100 Cr39.9%
Export₹151 Cr60.1%
Capital Structure (₹ Cr)
YearFace ValueAuthorisedIssuedPaid-up
2026₹10252222
Corporate Actions
TypeDateValueRemark
forthcoming2026-07-24Board Meetings
Related-Party Transactions (₹ Cr)
YearSubsidiariesAssociatesJVKMPOthersTotal
2025000404
2025000303
2025000202
Company Information
Incorporated2004
ChairmanSanjay S Shah.
AuditorJ S Shah & Co
Investor Email[email protected]
🌐 www.sakarhealthcare.com

📍 10/13 Nr MN Desai Petrol Pump, Sarkhej Bavla Highway, Changodar, Gujarat, 382213

Technical AnalysisPremium

Technical analysis (Premium)

Log in to see RSI, MACD, moving averages, oscillators and pivot levels for this stock.

More stocks

Prices are delayed/indicative; pros & cons are AI generated. Informational only — not investment advice. ← Back to search